一种新的抗病毒剂 A New Anti-viral Agent

一种分离纯化的新型抗病毒剂。其氨基酸序列是全新的,与已知序列的同一性不超过35%。抗病毒活性被证实对HIV-1和HSV-2。目前正在研究的有8种病毒,包括非典病毒19和20种微生物。该多肽、缀合物、融合蛋白和包含完整多肽或其氨基酸序列连续部分的组合物抑制宿主的病毒感染。这种抗病毒多肽、其缀合物或融合蛋白和组合物的生产方法。提供了预防性或治疗性抑制宿主病毒感染的方法。不同HIV-1株系的半最大抑制浓度(IC50)范围为0.05 - 60纳米,这是此类抗病毒药物的最佳公布值范围。此外,其在碱性条件下的高稳定性,在治疗浓度范围内无细胞毒性和促有丝分裂作用,优于具有相同抗病毒作用机制的已知蛋白质。基于这种蛋白质的治疗概念被认为能够触及艾滋病毒的致命弱点。 An isolated and purified a new anti-viral agent. Its amino acid sequence is completely new with no higher than 35% identity with known sequences. Anti-viral activity was confirmed against HIV-1 and HSV-2. Currently under research are 8 viruses including SARS-CoV-19 and 20 microbes. This polypeptide, conjugates, fusion proteins and compositions comprising whole polypeptide or continuous parts of its amino acid sequence, inhibit a viral infection of a host. Method of production of this anti-viral polypeptide, its conjugates or fusion proteins and compositions. Provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host. Half maximal inhibitory concentration (IC50) for different HIV-1 strains ranges from 0.05 - 60 nM, which is in the range of the best published values for this type of antiviral agents. Moreover, its high stability under alkaline conditions, absence of cytotoxicity and of mitogenic effect in the range of therapeutic concentrations are advantages over known proteins of the same mechanism of anti-viral action. The therapeutic concept based on this type of proteins is seen as capable to hit the Achilles heel of HIV.